Creating a Better Pathologist
Cart 0

2019, April 3-5: Diagnostic Challenges in Hematopathology

$1,349.00

Apr. 3-5, 2019

14.5 CME / 14.5 SAMs

Course Schedule     Faculty Biographies

 

COURSE DESCRIPTION

Hematopoietic neoplasms are highly heterogeneous, composed of numerous clinicopathologic subtypes and variants, and may present at many organ sites.  The diagnostic evaluation of lymphomas and hematopoietic neoplasms presenting at nodal and extra-nodal sites requires careful integration of histologic, immunophenotypic, clinical and molecular features.  Furthermore, rapid advances in the genetic/genomic understanding of these diseases pose a significant challenge to staying abreast of the diagnostic criteria, immunophenotypic and molecular prognostic/therapeutic markers that have clinical impact.  This is underscored by diminishing sample sizes in biopsies of extra-nodal lesions and needle core biopsies of lymph nodes.  In addition, the role of the pathologist as integrators of information is expanding rapidly.

This educational activity will highlight practical aspects representing important changes that impact the diagnostic approach to challenging extra-nodal hematopoietic neoplasms, cutaneous lymphomas, T-cell lymphomas and needle core biopsies from lymph nodes.  Experience one-on-one learning from experts who will share their varied and profound experience in an aesthetic and dynamic venue, recalling the clinical sign-out of your training years.

COURSE OBJECTIVES 

  • Develop diagnostic approaches to challenging extra-nodal hematopoietic neoplasms, cutaneous lymphomas, T-cell lymphomas and needle core biopsies from lymph nodes
  • Facilitate better use of immunohistochemical and molecular studies to identify clinically relevant subtypes of cutaneous lymphomas and T-cell lymphomas
  • Improve ability to distinguish the subtypes of T-cell lymphomas
  • Refine skills to distinguish subtypes of hematopoietic neoplasms that present in extra-nodal sites
  • Enhance capacity to evaluate lymphomas for clinically-relevant therapeutic targets

COURSE DIRECTOR

  • Megan S. Lim, M.D., Ph.D.
    University of Pennsylvania / Perelman School of Medicine

FACULTY

  • Dale M. Frank, M.D.
    University of Pennsylvania / Perelman School of Medicine
  • Alejandro A. Gru, M.D.
    University of Virginia
  • Elaine S. Jaffe, M.D.
    National Cancer Institute/NIH
  • Joseph D. Khoury, M.D.
    University of Texas, MD Anderson Cancer Center

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABPath requirements for Continuing Certification (CC).

Physicians can earn a maximum of 14.5 SAM credit hours.

USCAP records courses at the Interactive Learning Center for future educational purposes. By registering for this course, you consent that your likeness may be used by USCAP.

 

CANCELLATION POLICY

For cancellations received one month or more before the course starts, a $50 administrative charge will be due. After that date, cancellations will be assessed an administrative charge of 25% of the total registration fee. There will be no refunds for cancellations one week before the event.

The Academy is not responsible for travel expenses incurred as a result of an event cancellation.



More from this collection